TABLE 2

Associations between indoor particulate matter concentration and chronic obstructive pulmonary disease health outcomes by weight

Health outcomesNon-obese participantsObese participantsInteraction
β-coefficient/OR (95% CI)p-valueβ-coefficient/OR (95% CI)p-valuep-value
Indoor PM2.5
 Rescue inhaler use#0.03 (−0.13–0.19)0.700.14 (0.01–0.26)0.040.28
 Nocturnal symptomsOR 0.11 (0.01–1.31)0.08OR 1.84 (1.16–2.90)<0.010.03
 mMRC dyspnoea scale−0.01 (−0.21–0.18)0.890.20 (0.05–0.34)<0.010.07
 SGRQ total score0.17 (−2.51–2.85)0.902.40 (0.55–4.27)0.010.17
 Frequency of wheeze0.06 (−0.18–0.31)0.610.27 (0.07–0.50)<0.010.18
 ExacerbationsOR 0.99 (0.34–2.89)0.99OR 1.53 (1.04–2.26)0.030.53
Indoor PM2.5−10
 Rescue inhaler use#−0.13 (−0.56–0.29)0.540.33 (0.13–0.53)<0.010.05
 Nocturnal symptomsOR 0.06 (0.001–6.18)0.23OR 5.93 (1.24–28.28)0.030.04
 mMRC dyspnoea scale0.11 (−0.41–0.62)0.690.73 (0.28–1.19)<0.010.07
 SGRQ total score0.59 (−6.03–7.20)0.86−0.98 (−6.43–4.47)0.720.98
 Frequency of wheeze−0.02 (−0.64–0.59)0.94−0.31 (−0.96–0.34)0.350.97
 ExacerbationsOR 1.50 (0.02–104.47)0.85OR 5.1 (0.93–28.03)0.060.37
  • For dichotomous outcomes, point estimates represent odds ratios (OR). β-coefficients/OR were calculated based on a 10 µg·m−3 change in particulate matter concentration. Models are adjusted for age, sex, education and baseline forced expiratory volume in 1 s. PM2.5: particulate matter with an aerodynamic size ≤2.5 μm; mMRC: modified Medical Research Council; SGRQ: St George's Respiratory Questionnaire; PM2.5−10: particulate matter with an aerodynamic size 2.5–10 μm. #: rescue inhaler use is represented as daily average use during the week-long monitoring period; : wheeze was assessed using a five-point Likert scale that ascertained frequency in the past 4 weeks.